Atossa Genetics Inc. (NASDAQ:ATOS) Given Average Recommendation of “Hold” by Analysts

Shares of Atossa Genetics Inc. (NASDAQ:ATOS) have received a consensus rating of “Hold” from the five analysts that are currently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, two have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $95.00.

Several brokerages have recently commented on ATOS. Weiss Ratings reiterated a “sell (d-)” rating on shares of Atossa Genetics in a research report on Wednesday, January 21st. Ascendiant Capital Markets upped their target price on Atossa Genetics from $116.25 to $120.00 and gave the stock a “buy” rating in a research note on Monday, December 8th.

Hedge Funds Weigh In On Atossa Genetics

A number of large investors have recently added to or reduced their stakes in ATOS. Hudson Bay Capital Management LP bought a new stake in Atossa Genetics in the second quarter worth $26,000. Gallagher Capital Advisors LLC purchased a new position in shares of Atossa Genetics in the third quarter worth about $27,000. JPMorgan Chase & Co. lifted its stake in shares of Atossa Genetics by 1,294.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock valued at $33,000 after acquiring an additional 35,474 shares during the last quarter. Catalyst Funds Management Pty Ltd purchased a new stake in Atossa Genetics during the 2nd quarter valued at about $49,000. Finally, Bank of America Corp DE grew its position in Atossa Genetics by 55.7% during the 2nd quarter. Bank of America Corp DE now owns 99,601 shares of the company’s stock worth $83,000 after acquiring an additional 35,629 shares during the last quarter. Hedge funds and other institutional investors own 12.74% of the company’s stock.

Atossa Genetics Stock Up 6.6%

ATOS opened at $4.20 on Tuesday. The business’s fifty day simple moving average is $8.89 and its 200 day simple moving average is $11.31. Atossa Genetics has a 52 week low of $3.76 and a 52 week high of $19.35. The stock has a market cap of $36.20 million, a PE ratio of -1.17 and a beta of 1.36.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.